Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (131-140 of 159) with videos related to

Pageof 16
Sort By:
The Journal of Rheumatology|September 17, 2014
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonistMark C Genovese, Désirée M van der Heijde, Edward C Keystone, et al.
The Journal of Rheumatology|May 17, 2012
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trialDésirée van der Heijde, Edward C Keystone, Jeffrey R Curtis, et al.
Current Medical Research and Opinion|January 6, 2006
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyAllan Gibofsky, William R Palmer, John A Goldman, et al.
ACR Open Rheumatology|October 28, 2021
A Bridge Too Far? Real-World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis CohortKathleen M Andersen, Orit Schieir, Marie-France Valois, et al.
Rheumatology Advances in Practice|June 19, 2024
Risk factors for prevalent and incident hypertension in rheumatoid arthritis: data from the Canadian Early Arthritis CohortBrook Hadwen, Saverio Stranges, Janet E Pope, et al.
Annals of the Rheumatic Diseases|August 12, 2017
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM studyEdward C Keystone, Peter C Taylor, Yoshiya Tanaka, et al.
Arthritis and Rheumatism|November 30, 2006
Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian populationWilliam G Newman, Qing Zhang, Xiangdong Liu, et al.
Arthritis Care & Research|December 2, 2017
Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort StudyElizabeth Schulman, Susan J Bartlett, Orit Schieir, et al.
Annals of the Rheumatic Diseases|November 29, 2014
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateEdward C Keystone, Peter C Taylor, Edit Drescher, et al.
Arthritis Care & Research|May 22, 2019
Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective CohortCristiano S Moura, Orit Schieir, Marie-France Valois, et al.
Pageof 16

Showing results (131-140 of 159) with videos related to

Sort By:
Pageof 16
The Journal of Rheumatology|September 17, 2014
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonistMark C Genovese, Désirée M van der Heijde, Edward C Keystone, et al.
The Journal of Rheumatology|May 17, 2012
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trialDésirée van der Heijde, Edward C Keystone, Jeffrey R Curtis, et al.
Current Medical Research and Opinion|January 6, 2006
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyAllan Gibofsky, William R Palmer, John A Goldman, et al.
ACR Open Rheumatology|October 28, 2021
A Bridge Too Far? Real-World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis CohortKathleen M Andersen, Orit Schieir, Marie-France Valois, et al.
Rheumatology Advances in Practice|June 19, 2024
Risk factors for prevalent and incident hypertension in rheumatoid arthritis: data from the Canadian Early Arthritis CohortBrook Hadwen, Saverio Stranges, Janet E Pope, et al.
Annals of the Rheumatic Diseases|August 12, 2017
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM studyEdward C Keystone, Peter C Taylor, Yoshiya Tanaka, et al.
Arthritis and Rheumatism|November 30, 2006
Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian populationWilliam G Newman, Qing Zhang, Xiangdong Liu, et al.
Arthritis Care & Research|December 2, 2017
Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort StudyElizabeth Schulman, Susan J Bartlett, Orit Schieir, et al.
Annals of the Rheumatic Diseases|November 29, 2014
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateEdward C Keystone, Peter C Taylor, Edit Drescher, et al.
Arthritis Care & Research|May 22, 2019
Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective CohortCristiano S Moura, Orit Schieir, Marie-France Valois, et al.
Pageof 16